Biotechnology, electronics and life science company MOBILion Systems, Inc. announced on Wednesday a collaboration with Dr Oliver Schmitz from the University of Duisburg-Essen, a specialist in analytical chemistry for complex sample analysis.
This partnership highlights MOBILion's commitment to advancing multiomics research through its proprietary SLIM (Structures for Lossless Ion Manipulation) technology.
Dr Schmitz will integrate MOBILion's latest low mass system into his work on complex sample analysis, including Chinese herbal medicine and multidimensional chromatography workflows. The system addresses limitations of traditional LC-MS and ion mobility technologies, enabling precise and efficient metabolomics discovery. Cleaner, more focused data is achieved by reducing overlapping signals, simplifying molecular identification and interpretation.
MOBILion continues to expand its SLIM-based product pipeline, supporting breakthroughs in proteomics, lipidomics, glycomics, and metabolomics. This collaboration builds on the company's recent progress in proteomics applications and commercial platform development.
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Eli Lilly and Co receives approval from FDA for Zepbound
YolTech Therapeutics updates data from Phase I/IIa clinical trial of YOLT-201
AstraZeneca's Tagrisso gains EU approval for advanced lung cancer treatment
Novo Nordisk's CagriSema shows superior weight loss in obesity trial
GSK's Jemperli-Zejula combination shows promise in ovarian cancer
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
BioArctic licenses PyroGlu-Aβ antibody programme to Bristol Myers Squibb
Thor Medical signs supply deal with AdvanCell
MOBILion Systems collaborates with Dr Oliver Schmitz to enhance metabolomics analysis
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial